Crossmark

Management of NAFLD: a stage-based approach

Crossref DOI link: https://doi.org/10.1038/nrgastro.2016.3

Published Online: 2016-02-24

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rinella, Mary E.

Sanyal, Arun J.
License Information

Text and Data Mining valid from 2016-02-24
More Information

Article History

First Online: 24 February 2016

Competing interests

: M.E.R. has served as a consultant to AbbVie, FibroGen, Genentech, Intercept, NGM Biopharmaceuticals, NuSirt, Shire, Takeda and W.L Gore & Associates. A.J.S. has stock options in Genfit. He is the President of Sanyal Biotechnologies and has served as a consultant to AbbVie, Astra Zeneca, Boehringer Ingelhiem, Exalenz Bioscience, FibroGen, Genfit, Hemoshear, Immune Pharma, Immuron, Lilly, Nimbus Therapeutics, Nitto Denko, Salix Pharmaceuticals, Takeda and Tobira Therapeutics. He has been an unpaid consultant to Echosens and Intercept Pharmaceuticals. His institution has received grant support from Astra Zeneca, Bristol Myers, Gilead, Merck, Novartis, Salix Pharmaceuticals and Tobira Therapeutics.